Why Continuous Hormone Monitoring Could Transform Women's Health Monitoring

Ida Tin, who coined “femtech” and founded Clue, is leading a €40 million SPRIND challenge in Europe focused on continuous hormone monitoring.
Eight teams were selected to compete to build biosensors that can measure at least four hormones continuously for seven days.
Tin says hormones remain a “black box” in medicine, and current care is built around a male baseline that ignores hormonal variability.
The article argues that missing continuous hormone data contributes to long delays in diagnosing conditions like endometriosis and PCOS.
Continuous hormone monitoring could also improve the effectiveness of treatments such as IVF.
SPRIND is building the first standardized continuous hormone dataset across ages, ethnicities, life stages, and health conditions.
The competing teams are exploring different technologies, including sweat sensors, optical sensing, skin patches, implants, enzymatic systems, and photonic wearables.
Tin says the biggest barrier is not only funding or regulation but also broader cultural awareness around women’s health.
Clue, Tin’s earlier company, is a reproductive health app with over 100 million downloads in 190 countries and FDA clearance as a digital contraceptive.

Your notes

Save this item to your library to add private notes.

Ida Tin popularized the term FemTech back in the day

@schayeJul 24, 2026